Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice
Iris Valdés(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Laura Lazo(Centro de Ingeniería Genética y Biotecnología), Edith Suzarte(Centro de Ingeniería Genética y Biotecnología), Ania Cabrales(Centro de Ingeniería Genética y Biotecnología), Carlos A. Guzmán(Helmholtz Centre for Infection Research), Karem Cobas(Centro de Ingeniería Genética y Biotecnología), José Antônio Silva(Universidade Nove de Julho), Julio C. Aguilar(Centro de Ingeniería Genética y Biotecnología), Yusleidi Pérez(Centro de Ingeniería Genética y Biotecnología), Rocío Garateix(Centro de Ingeniería Genética y Biotecnología)
Cited by 5
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134